Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: The therapy options for patients with advanced NETs are limited. The mTOR inhibitors (mTORi), Torin1 and NVP-BEZ235, are known to suppress cell proliferation in NETs. However, cancer cells may use mTORi-induced autophagy to prolong survival, evading the anti-cancer effect. Chloroquine (CQ) and hydroxychloroquine (HCQ) have been shown to inhibit autophagy.
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author: Avniel- Polak S
Authors: Avniel-Polak S, Leibowitz G, Glaser B, Gross D, Grozinsky-Glasberg S,
Introduction: Most patients with neuroendocrine tumors (NETs) require systemic treatment, often with a limited therapeutic effect. RAD001 and Torin1 are mTOR inhibitors (mTORi) known to suppress cell proliferation in NETs. However, cancer cells may use mTORi-induced autophagy to escape the anti-proliferative effect and to prolong cell survival. Chloroquine (CQ) and hydroxychloroquine (HCQ) inhibit autophagy.
Conference: 11th Annual ENETSConcerence (2014)
Presenting Author: Glasberg S
Authors: Avniel-Polak S, Leibowitz G, Glaser B, Gross D, Glasberg S,
Keywords: NETs, autophagy, mTOR inhibitors,
Introduction: Torin1, a new mTOR inhibitor that globally inhibits both mTORC1 and mTORC2, seems to impair cell growth and proliferation to a greater degree than rapamycin; its effects in NET cells are unknown.
Conference: 8th Annual ENETSConcerence (2011)
Presenting Author:
Authors: Grozinsky-Glasberg S, Rubinfeld H, Cohen O, Greif F, Kammer A,
Keywords: Torin1, RAD001, NETs, antiproliferation, Akt, mTOR, HDACi,